Atopic Dermatitis Eczema Clinical Trial
Official title:
Temperature Controlled Laminar Airflow (TLA) Treatment of Moderate to Severe Atopic Eczema in Children and Adolescents - a Randomized Placebo Controlled Phase 2 Study
This is a single centre randomised, placebo-controlled phase 2 study in which 96 children age 4 to 16 years with moderate to severe, longstanding allergic eczema will be enrolled.
Following a 4 to 6 week period on standardised treatment (run-in period, to ensure everyone starts with the same treatment approach), participants will be randomised to an active or dummy temperature-controlled laminar airflow (TLA) device, which has been shown to markedly reduce exposure to particles which can cause allergic reactions when being inhaled (inhaled allergens) and other particles which are in the air the investigators breathe in. This has been shown to be an effective treatment of atopic asthma. The participants will undergo a 12-week treatment period. The device will then be removed and a final follow-up visit occurs at 16 weeks. The total study duration, including the run-in period is up to 22 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05579899 -
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
|
Phase 2 | |
| Terminated |
NCT04085549 -
Effects of a Berry Oil Cream on Atopic Eczema and Skin
|
N/A | |
| Recruiting |
NCT05578482 -
Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis
|
Phase 4 | |
| Completed |
NCT03540043 -
Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis
|
Phase 2 | |
| Recruiting |
NCT03293030 -
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
|
Phase 4 | |
| Completed |
NCT03386032 -
8-Week Atopic Dermatitis (AD) Treatment Study
|
Phase 3 | |
| Completed |
NCT03667014 -
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
|
Phase 4 | |
| Terminated |
NCT05382819 -
A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis
|
Phase 1 | |
| Completed |
NCT04537468 -
Development of a Method to Measure mRNA Levels in Skin Samples
|
N/A | |
| Completed |
NCT03268174 -
Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.
|
N/A | |
| Active, not recruiting |
NCT03859986 -
Study in Subjects With Moderate Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04800185 -
Characterizing Skin Microbiome Change in Atopic Dermatitis
|
Early Phase 1 | |
| Completed |
NCT06361992 -
Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children
|
Phase 3 | |
| Recruiting |
NCT06024499 -
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
|
Phase 2 | |
| Recruiting |
NCT03742414 -
Seal, Stopping Eczema and Allergy Study
|
Phase 3 | |
| Completed |
NCT03090178 -
Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy
|
N/A | |
| Recruiting |
NCT05935085 -
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).
|
Phase 2 | |
| Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
| Completed |
NCT04773587 -
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
|
Phase 3 | |
| Active, not recruiting |
NCT04017520 -
Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time
|